The role of adjuvant chemotherapy in stage II colorectal cancer patients
Tóm tắt
Adjuvant chemotherapy use in stage II colorectal cancer (CRC) is debated. We evaluated the prognostic significance of clinicopathological features recommended by most guidelines for identifying high-risk stage II CRC and adjuvant chemotherapeutic response. We enrolled 1,039 stage II CRC patients who underwent curative surgery at Taipei Veterans General Hospital from January 2005 to December 2010. Seventy-seven patients who received radiotherapy were excluded. The endpoint was disease-free survival. Of 962 patients, 37 had stage T4 tumors; 50, lymphovascular invasion; 39, poor differentiation; 249, preoperative carcinoembryonic antigen (CEA) levels >5 ng/mL; and 53 underwent emergent operations. One hundred ninety-four patients received 5-fluorouracil-based adjuvant chemotherapy. During a median follow-up period of 60.2 months, recurrence developed in 110 patients (11.4 %). The 5-year disease-free survival (DFS) was 87.6 %. In multivariate analysis, preoperative CEA >5 ng/ml (p = 0.001), emergent operation for obstruction/perforation (p = 0.008), lymphovascular invasion (p = 0.014), and T4 disease (p = 0.030) were significantly associated with poor DFS. High-risk stage II patients (n = 484) benefited from adjuvant chemotherapy (5-year DFS with and without adjuvant chemotherapy, 87.3 vs. 78.9 %; p = 0.028). Adjuvant chemotherapy improved DFS in high-risk stage II CRC patients, but not in low-risk patients.
Tài liệu tham khảo
Cancer registry annual report (2010) (2013) The Department of Health, the Executive Yuan, Taiwan, ROC
Jessup JM, McGinnis LS, Steele GD Jr, Menck HR, Winchester DP (1996) The National Cancer Data Base. Report on colon cancer. Cancer 78(4):918–926. doi:10.1002/(SICI)1097-0142(19960815)78:4
Ju JH, Chang SC, Wang HS, Yang SH, Jiang JK, Chen WC, Lin TC, Hung H, Wang FM, Lin JK (2007) Changes in disease pattern and treatment outcome of colorectal cancer: a review of 5,474 cases in 20 years. Int J Color Dis 22(8):855–862. doi:10.1007/s00384-007-0293-z
O'Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96(19):1420–1425. doi:10.1093/jnci/djh275
NIH consensus conference (1990) Adjuvant therapy for patients with colon and rectal cancer. JAMA: J Am Medical Assoc 264(11):1444–1450
Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol: Off J Am Soc Clin Oncol 22(10):1797–1806. doi:10.1200/JCO.2004.09.059
Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, McCormack GW, Gerstner JB, Krook JE, Malliard J et al (1989) Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol Off J Am Soc Clin Oncol 7(10):1447–1456
Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH et al (1995) Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. J Clin Oncol: Off J Am Soc Clin Oncol 13(12):2936–2943
Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charette M, Haller DG (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol: Off J Am Soc Clin Oncol 22(16):3408–3419. doi:10.1200/JCO.2004.05.063
Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L (2004) Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol: Off J Am Soc Clin Oncol 22(16):3395–3407. doi:10.1200/JCO.2004.03.087
Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370(9604):2020–2029. doi:10.1016/S0140-6736(07)61866-2
Tournigand C, de Gramont A (2011) Chemotherapy: is adjuvant chemotherapy an option for stage II colon cancer? Nature Rev Clin Oncol 8(10):574–576. doi:10.1038/nrclinonc.2011.139
Lin CC, Lin JK, Chang SC, Wang HS, Yang SH, Jiang JK, Chen WS, Lin TC (2009) Is adjuvant chemotherapy beneficial to high risk stage II colon cancer? Analysis in a single institute. Int J Color Dis 24(6):665–676. doi:10.1007/s00384-009-0634-1
Investigators (1999) Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2). J Clin Oncol Off J Am Soc Clin Oncol 17(5):1356–1363
Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, Hammond ME, Henson DE, Hutter RV, Nagle RB, Nielsen ML, Sargent DJ, Taylor CR, Welton M, Willett C (2000) Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124(7):979–994. doi:10.1043/0003-9985(2000)124 , < 0979:PFICC > 2.0.CO;2
Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17(6):1471–1474. doi:10.1245/s10434-010-0985-4
Jonker DJ, Spithoff K, Maroun J (2011) Adjuvant systemic chemotherapy for stage II and III colon cancer after complete resection: an updated practice guideline. Clin Oncol (R Coll Radiol) 23(5):314–322. doi:10.1016/j.clon.2011.02.010
Stocchi L, Fazio VW, Lavery I, Hammel J (2011) Individual surgeon, pathologist, and other factors affecting lymph node harvest in stage II colon carcinoma. is a minimum of 12 examined lymph nodes sufficient? Ann Surg Oncol 18(2):405–412. doi:10.1245/s10434-010-1308-5
Otchy D, Hyman NH, Simmang C, Anthony T, Buie WD, Cataldo P, Church J, Cohen J, Dentsman F, Ellis CN, Kilkenny JW 3rd, Ko C, Moore R, Orsay C, Place R, Rafferty J, Rakinic J, Savoca P, Tjandra J, Whiteford M (2004) Practice parameters for colon cancer. Dis Colon Rectum 47(8):1269–1284
Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA (2013) Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Comprehensive Cancer Network: JNCCN 11(5):519–528
Engstrom PF, Arnoletti JP, Benson AB 3rd, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J Jr, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C (2009) NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Comprehensive Cancer Network : JNCCN 7(8):778–831
Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Landmann RG, Guillem JG, Paty PB, Temple LK, Wong WD, Weiser MR (2008) Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum 51(5):503–507. doi:10.1007/s10350-008-9246-z
Chen HS, Sheen-Chen SM (2000) Obstruction and perforation in colorectal adenocarcinoma: an analysis of prognosis and current trends. Surgery 127(4):370–376
Jestin P, Nilsson J, Heurgren M, Pahlman L, Glimelius B, Gunnarsson U (2005) Emergency surgery for colonic cancer in a defined population. British J Surg 92(1):94–100. doi:10.1002/bjs.4780
Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Kohne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol: Off J Eur Soc Med Oncol / ESMO 23(10):2479–2516. doi:10.1093/annonc/mds236
Nelson H, Petrelli N, Carlin A, Couture J, Fleshman J, Guillem J, Miedema B, Ota D, Sargent D (2001) Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 93(8):583–596
Schofield JB, Mounter NA, Mallett R, Haboubi NY (2006) The importance of accurate pathological assessment of lymph node involvement in colorectal cancer. Colorectal Dis: Off J Assoc Coloproctol Great Britain Ireland 8(6):460–470. doi:10.1111/j.1463-1318.2006.01044.x
Smith AJ, Driman DK, Spithoff K, Hunter A, McLeod RS, Simunovic M, Langer B (2010) Guideline for optimization of colorectal cancer surgery and pathology. J Surg Oncol 101(1):5–12. doi:10.1002/jso.21395
Baxter NN, Virnig DJ, Rothenberger DA, Morris AM, Jessurun J, Virnig BA (2005) Lymph node evaluation in colorectal cancer patients: a population-based study. J Natl Cancer Inst 97(3):219–225. doi:10.1093/jnci/dji020
Berger AC, Watson JC, Ross EA, Hoffman JP (2004) The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 70(3):235–240, discussion 240
Bui L, Rempel E, Reeson D, Simunovic M (2006) Lymph node counts, rates of positive lymph nodes, and patient survival for colon cancer surgery in Ontario, Canada: a population-based study. J Surg Oncol 93(6):439–445. doi:10.1002/jso.20499
Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA (2007) Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 99(6):433–441. doi:10.1093/jnci/djk092
Ogata Y, Murakami H, Sasatomi T, Ishibashi N, Mori S, Ushijima M, Akagi Y, Shirouzu K (2009) Elevated preoperative serum carcinoembrionic antigen level may be an effective indicator for needing adjuvant chemotherapy after potentially curative resection of stage II colon cancer. J Surg Oncol 99(1):65–70. doi:10.1002/jso.21161
Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol: Off J Am Soc Clin Oncol 24(33):5313–5327. doi:10.1200/JCO.2006.08.2644